Grimes & Company’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$739K Sell
4,716
-42
-0.9% -$6.3K 0.02% 285
2026
Q1
$727K Buy
4,758
+120
+3% +$18.4K 0.02% 269
2025
Q4
$639K Buy
4,638
+287
+7% +$37.6K 0.02% 290
2025
Q3
$558K Sell
4,351
-177
-4% -$21.6K 0.01% 300
2025
Q2
$548K Sell
4,528
-94
-2% -$10.6K 0.01% 259
2025
Q1
$515K Buy
4,622
+135
+3% +$14.4K 0.02% 237
2024
Q4
$437K Sell
4,487
-84
-2% -$8.96K 0.01% 267
2024
Q3
$526K Buy
4,571
+16
+0.4% +$1.81K 0.01% 233
2024
Q2
$485K Sell
4,555
-9,967
-69% -$1M 0.01% 222
2024
Q1
$1.4M Sell
14,522
-478
-3% -$49K 0.04% 152
2023
Q4
$1.51M Sell
15,000
-785
-5% -$75.8K 0.05% 149
2023
Q3
$1.61M Sell
15,785
-1,426
-8% -$145K 0.06% 135
2023
Q2
$1.74M Sell
17,211
-121,877
-88% -$12.2M 0.06% 131
2023
Q1
$12.8M Sell
139,088
-3,603
-3% -$315K 0.52% 45
2022
Q4
$12.9M Buy
142,691
+45
+0% +$3.79K 0.55% 38
2022
Q3
$10.8M Buy
142,646
+1,341
+0.9% +$111K 0.57% 41
2022
Q2
$11.9M Buy
141,305
+2,347
+2% +$206K 0.6% 36
2022
Q1
$12.2M Buy
138,958
+48,186
+53% +$4.17M 0.64% 50
2021
Q4
$7.94M Buy
90,772
+2,205
+2% +$183K 0.36% 67
2021
Q3
$7.24M Buy
88,567
+2,696
+3% +$243K 0.32% 71
2021
Q2
$7.83M Buy
85,871
+1,787
+2% +$159K 0.34% 69
2021
Q1
$7.19M Buy
84,084
+2,631
+3% +$236K 0.35% 73
2020
Q4
$7.69M Buy
81,453
+1,477
+2% +$129K 0.4% 67
2020
Q3
$6.95M Buy
79,976
+12,186
+18% +$1.06M 0.44% 64
2020
Q2
$5.92M Sell
67,790
-673
-1% -$58.1K 0.41% 68
2020
Q1
$5.64M Buy
68,463
+224
+0.3% +$20K 0.52% 49
2019
Q4
$6.46M Buy
68,239
+517
+0.8% +$46.4K 0.42% 62
2019
Q3
$5.88M Buy
67,722
+1,170
+2% +$105K 0.42% 62
2019
Q2
$6.08M Sell
66,552
-5,763
-8% -$488K 0.46% 62
2019
Q1
$6.23M Buy
72,315
+65
+0.1% +$5.22K 0.49% 63
2018
Q4
$5.55M Sell
72,250
-804
-1% -$62.6K 0.54% 54
2018
Q3
$5.64M Sell
73,054
-20,033
-22% -$1.48M 0.45% 63
2018
Q2
$6.3M Sell
93,087
-814
-0.9% -$56.2K 0.56% 58
2018
Q1
$6.8M Buy
93,901
+1,867
+2% +$142K 0.66% 48
2017
Q4
$6.92M Buy
92,034
+56,716
+161% +$4.28M 0.67% 47
2017
Q3
$2.72M Sell
35,318
-1,227
-3% -$92.7K 0.29% 76
2017
Q2
$2.73M Sell
36,545
-63,949
-64% -$4.53M 0.3% 77
2017
Q1
$6.69M Buy
100,494
+10,847
+12% +$723K 0.73% 37
2016
Q4
$5.85M Sell
89,647
-5,030
-5% -$326K 0.68% 42
2016
Q3
$6.7M Sell
94,677
-3,134
-3% -$228K 0.9% 30
2016
Q2
$7.23M Buy
97,811
+9,337
+11% +$645K 0.97% 21
2016
Q1
$5.74M Sell
88,474
-3,365
-4% -$229K 0.74% 35
2015
Q4
$7.08M Buy
91,839
+90
+0.1% +$7.15K 0.96% 17
2015
Q3
$7.56M Sell
91,749
-3,935
-4% -$350K 0.97% 15
2015
Q2
$8.43M Buy
95,684
+803
+0.8% +$73.7K 1.19% 15
2015
Q1
$8.38M Buy
94,881
+2,021
+2% +$179K 2.02% 8
2014
Q4
$7.71M Sell
92,860
-829
-0.9% -$68.7K 1.99% 8
2014
Q3
$7.9M Sell
93,689
-2,557
-3% -$207K 2.07% 7
2014
Q2
$7.81M Buy
96,246
+973
+1% +$76.5K 2.05% 6
2014
Q1
$7.26M Buy
95,273
+3,441
+4% +$251K 2.04% 8
2013
Q4
$6.61M Buy
91,832
+3,141
+4% +$218K 1.98% 10
2013
Q3
$6.1M Buy
88,691
+4,204
+5% +$278K 2.06% 7
2013
Q2
$5.35M Buy
+84,487
New +$5.5M 1.95% 13

Other funds holding NVS

Grimes & Company's NVS Position: Q2 2026 in Review

Grimes & Company reduced its Novartis (NVS) stake by 0.88% in Q2 2026, selling an estimated $6.3K and leaving 4,716 shares worth $739K. The position accounts for 0.02% of the portfolio, ranked #285.

Grimes & Company first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.9M in Q4 2022. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Grimes & Company held 4,716 shares of Novartis worth $739K as of Q2 2026.
  • Grimes & Company sold 42 Novartis shares in Q2 2026, an estimated $6.3K.
  • Novartis made up 0.02% of Grimes & Company's portfolio in Q2 2026, its #285 holding.
  • Grimes & Company first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Grimes & Company's Novartis position peaked at $12.9M in Q4 2022.
  • 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.